A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

May 31, 2027

Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Interventions
BIOLOGICAL

Efgartigimod PH20 SC

Subcutaneous injection of efgartigimod PH20 SC

Trial Locations (12)

33486

RECRUITING

EZR Research, Boca Raton

33705

RECRUITING

Baycare Medical Group, St. Petersburg

33952

RECRUITING

Medsol Clinical Research Center Inc, Port Charlotte

37403

RECRUITING

Erlanger Neuroscience Institute, Chattanooga

44195

RECRUITING

Cleveland Clinic, Cleveland

48202

RECRUITING

Henry Ford Health System, Detroit

62269

RECRUITING

HSHS Medical Group, O'Fallon

78681

RECRUITING

Central Texas Neurology Consultants - Elligo, Round Rock

92037

RECRUITING

University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI), La Jolla

92270

RECRUITING

Samir Macwan, M.D., Inc. (S corporation), Rancho Mirage

96817

RECRUITING

Hawaii Pacific Neuroscience, Honolulu

08540

RECRUITING

Visionary Investigators Network, Princeton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY